Biovie (BIVI) Other Non-Current Assets (2022 - 2023)

Biovie (BIVI) posted Other Non-Current Assets of $4562.0 for Q1 2023, little changed sequentially from $4562.0 in Q4 2022.

Biovie (BIVI) Other Non-Current Assets (2022 - 2023) Analysis & Trends

Biovie has reported Other Non-Current Assets for 2 years, with the latest figure at $4562.0 in Q1 2023.

Quarterly Other Non-Current Assets changed N/A year-over-year to $4562.0 in Q1 2023, while the trailing twelve-month figure through Mar 2023 was $4562.0 (changed N/A YoY) and the FY2022 annual result came in at $4562.0, changed N/A from the prior year.
Other Non-Current Assets was little changed at $4562.0 in Q1 2023 per BIVI's latest filing, from $4562.0 in the prior quarter.
Over five years, Other Non-Current Assets peaked at $4562.0 in Q2 2022 and troughed at $4562.0 in Q2 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Other Non-Current Assets (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	1.25 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	2.31 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	124.00 Mn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	618.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	109.58 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	65.13 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	202.31 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	104.44 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	62.96 Mn
10	Biovie	14.17 Mn	14.17 Mn	-	-

Download Data